IGF2BP2 and colorectal carcinoma: METTL3 is reported to act as an oncogene and to maintain SOX2 expression through an m6A-IGF2BP2-dependent mechanism in CRC cells, indicating a potential biomarker panel for prognostic prediction in CRC [10].